Our Story

Hiantis was founded in 2014 in Milano (Italy) to turn into products and services, ideas stemmed out of founders’ experiences and expertise in clinical practice and microbiological research. 

2104: Establishment of the Company with the support of a public funding from ‘Italia Lavoro S.p.A’ (now ANPAL Servizi S.p.A.) through the Call ‘Manager to Work’. 

2016: Licensing to an Italian Medium Pharmaceutical Company of a Patent that protects pharmaceutical formulations for the prevention and treatment of osteoporosis. 

2018: Funding from the European Commission, within the Program Horizon 2020-SME Instrument-05-2016-2017 (Supporting innovative SMEs in the healthcare biotechnology sector), in partnership with Genefirst from Oxford (UK), of a Project for the development and clinical validation of in vitro diagnostic devices for the diagnosis of HPV cervical infection and the prevention of cervical cancer (https://cordis.europa.eu/project/id/806551/it). 

2019: Participation to ATMA-EC Platform, set up by BBMRI.it (the Italian hub of Biobanking and Biomolecular Research Infrastructure), an Expert Centre to accelerate clinical research with focus on biomarker verification and validation (https://www.bbmri-eric.eu/services/expert-centre/). 

2019: Opening of an Operational Site in Brescia (Italy) for the development and production of in-vitro diagnostic devices 

2020: Funding from Regione Lombardia (Azione I.1.b.1.3 dell’Asse 1 del POR FESR 2014- 2020) as a ‘ Measure to support the development of collaborations for the identification of therapies and diagnostic, protection and analysis systems to counter the Coronavirus emergency and other viral emergencies of the future’, in partnership with the Universities of Milano and Milano-Bicocca, the ASSTs of Bergamo and Monza and the Companies Copan S.p.A. of Brescia and Lutech S.p.A of Milano. 

2021: Acquisition of ISO 13845 Certificate from Bureau Veritas 

2021: First CE Marking of an In-vitro diagnostic device (IVD). Screen KIT nCoV-2/QUANTICOR, For the diagnosis and quantification of coronavirus 

Mission

(Hiantis Mission is) to create products and services to help to improve people’s health, by preventing diseases, facilitating their diagnosis and improving their treatment, through the understanding of what is already known and the search for new knowledge

Vision

No more suffering from health problems

People

Paolo RomanoHiantis Sole Administrator
Hiantis Founder, Paolo is a Dermatologist with experience in drug development and management from his previous work in Pharmaceutical Industry as Medical Director. He is inventor of patents regarding drug’s formulations in the field of bone and dermatological diseases and co-author of publications in international peer-reviewed scientific journals, in collaboration with Italian and Inter- national researchers.
Ivan ValliniPlanning and Technical Manager
Ivan is responsible of all phases of IVDs development and of the implementation of products marketing plans. In his past commitments he had trackable success in setting-up ISO-certified operative facilities for both molecular IVD services (Bianalisi S.r.l) as well as kits development and production (Biodiversity Spa, Bird S.r.l). His experience and expertise contribute to bringing the molecular in-vitro diagnostics tools at the market level. In addition to the Master’s Degree in Molecular Biology (University of Milan) he obtained the Medical Specialization in Genetics (University of Brescia).
Silvia PaganoniHead of Production
Silvia is responsible for the Kit Production and Quality Control process implementation and execution. She has specific tasks in the pre-industrialization phases leading to the HPV OncoPredict Kit realization and other molecular IVD Kits. In charge of process implementation for kit labelling and all aspects related to the logistics and tracking control (kits/samples). Silvia obtained her Master’s Degree in Medical Biotechnology (University of Brescia).
Erica FilippiniOperative Researcher
Erica is responsible of specific tasks for the analytical development and validation of new batches of the HPV OncoPredict Kit and other molecular IVD Kits. Erica obtained her Master’s Degree in Biodiversity and Biological Evolution (University of Milan) and gained her second level master of science in Biotecnology of human reproduction (University of Bologna).
Clementina CocuzzaHiantis Scientific Adviser in Clinical Microbiology
Clementina is Associate Professor of Clinical Microbiology and Head of the Laboratory of Clinical Microbiology and Virology at the University of Milano-Bicocca. She has acquired extensive experience in clinical microbiology also by working in Microbiology Laboratories of international institutions such as The London Hospital Medical School, The Rockefeller University, New York, and The Rickettsial Laboratory of CDC, Atlanta.
She achieved a Medical Degree (MBBS), a Biochemistry Degree (BSc) and a Master’s Degree in Clinical Microbiology (MSc) at the University of London, as well as a PhD in Clinical Microbiology at the University of Milan. She is author of several papers published in high quality international peer reviewed scientific journals and co-inventor of EU patent that protects a diagnostic algorithm for HPV infections leading to cancer.
She achieved a Medical Degree (MBBS), a Biochemistry Degree (BSc) and a Master Degree in Clinical Microbiology (MSc) at the University of London, as well as a PhD in Clinical Microbiology at the University of Milan. She is author of several papers published in high quality international peer reviewed scientific journals and co-inventor of EU patent that protects a diagnostic algorithm for HPV infections leading to cancer.

Discover The Future

Contact Us